Raymond James Financial
ATOS icon

Raymond James Financial’s Atossa Therapeutics ATOS Stock Holding History

Raymond James Financial’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-755
Closed -$6.68K – 5297
2025
Q4 		$6.68K Buy
755
+34
+5% +$430 ﹤0.01% 5148
2025
Q3 		$9.38K Sell
721
-133
-16% -$1.64K ﹤0.01% 4940
2025
Q2 		$10.6K Hold
854
– – ﹤0.01% 5902
2025
Q1 		$8.62K Sell
854
-400
-32% -$4.86K ﹤0.01% 4786
2024
Q4 		$17.8K Buy
+1,254
New +$24.5K ﹤0.01% 4735

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial's ATOS Position: Q1 2026 in Review

Raymond James Financial sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 755 shares — an estimated $6.68K sold.

Raymond James Financial first reported a position in ATOS in Q4 2024 and held it in 5 quarters. The position peaked at $17.8K in Q4 2024. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Raymond James Financial reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 755 Atossa Therapeutics shares in Q1 2026, an estimated $6.68K.
  • Raymond James Financial first reported a position in Atossa Therapeutics in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's Atossa Therapeutics position peaked at $17.8K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.